<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00260520</url>
  </required_header>
  <id_info>
    <org_study_id>06-03-1942</org_study_id>
    <nct_id>NCT00260520</nct_id>
  </id_info>
  <brief_title>LMWH to Prevent Preeclampsia and Fetal Growth Restriction</brief_title>
  <official_title>Low Molecular Weight Heparin Vs No Treatment in Pregnant Women With Previous Preeclampsia or Fetal Growth Restriction Who Were Heterozygote for Factor V Leiden or Prothrombin Gene G20210A Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florence</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florence</source>
  <brief_summary>
    <textblock>
      The objective of this trial will be to determine whether prophylactic low-molecular weight
      heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A
      prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe
      fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal
      growth restriction, or both.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this trial will be to determine whether prophylactic low-molecular weight
      heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A
      prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe
      fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal
      growth restriction, or both. We also will assess the effect of treatment on other indicators
      of maternal and neonatal complications, and the growth of fetal body composition in terms of
      fat and lean body mass.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>January 2002</start_date>
  <completion_date>December 2003</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Preeclampsia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalteparin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previous severe preeclampsia

          -  Previous severe fetal growth restriction

          -  Heterozygous Factor V Leiden

          -  Heterozygous G20210A prothrombin gene mutations

        Exclusion Criteria:

          -  renal disease

          -  chronic hypertension

          -  preexisting diabetes mellitus

          -  homozygosity for Factor V Leiden

          -  homozygosity for prothrombin G20210A mutation

          -  hyperhomocysteinemia

          -  protein C deficency

          -  protein S deficency

          -  antithrombin deficiency

          -  positive anticardiolipin antibodies

          -  positive lupus anticoagulant
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giorgio Mello, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Gynecology, Perinatology and Human Reproduction, University of Florence, Italy</affiliation>
  </overall_official>
  <verification_date>December 2003</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2005</study_first_submitted>
  <study_first_submitted_qc>November 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2005</study_first_posted>
  <last_update_submitted>March 3, 2006</last_update_submitted>
  <last_update_submitted_qc>March 3, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2006</last_update_posted>
  <keyword>Low molecular weight heparin</keyword>
  <keyword>Preeclampsia</keyword>
  <keyword>Fetal Growth Restriction</keyword>
  <keyword>Thrombophilia</keyword>
  <keyword>Factor V Leiden</keyword>
  <keyword>G20210A prothrombin gene mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

